Ageing and multiple sclerosis
The factor that is most relevant and strongly associated with the clinical course of multiple
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - Springer
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
Therapeutic advances in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …
causes significant disability and healthcare burden. The treatment of MS has evolved over …
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of …
Background The safety and efficacy of ocrelizumab in primary progressive multiple sclerosis
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Multiple sclerosis (MS) can be divided into four phenotypes based on clinical evolution. The
pathophysiological boundaries of these phenotypes are unclear, limiting treatment …
pathophysiological boundaries of these phenotypes are unclear, limiting treatment …
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
F Piehl - Journal of Internal Medicine, 2021 - Wiley Online Library
The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …
demyelinating and neurodegenerative disease of the central nervous system (CNS) …
Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis
A Calvi, FP Carrasco, C Tur, DT Chard, J Stutters… - Neurology, 2022 - AAN Enterprises
Background and Objective To explore the relationship between slowly expanding lesions
(SELs) on MRI and disability in secondary progressive multiple sclerosis (SPMS). Methods …
(SELs) on MRI and disability in secondary progressive multiple sclerosis (SPMS). Methods …
Multiple sclerosis pathogenesis and updates in targeted therapeutic approaches
ES Vasileiou, KC Fitzgerald - Current allergy and asthma reports, 2023 - Springer
Abstract Purpose of Review In this review, we provide a comprehensive update on current
scientific advances and emerging therapeutic approaches in the field of multiple sclerosis …
scientific advances and emerging therapeutic approaches in the field of multiple sclerosis …
Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study
A Genchi, E Brambilla, F Sangalli, M Radaelli… - Nature medicine, 2023 - nature.com
Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS),
combining neuroprotection and immunomodulation, represent an unmet need. Neural …
combining neuroprotection and immunomodulation, represent an unmet need. Neural …
Toward identifying key mechanisms of progression in multiple sclerosis
L Husseini, A Geladaris, MS Weber - Trends in Neurosciences, 2024 - cell.com
A major therapeutic goal in the treatment of multiple sclerosis (MS) is to prevent the
accumulation of disability over an often decades-long disease course. Disability progression …
accumulation of disability over an often decades-long disease course. Disability progression …